A5063068906- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Esophageal Cancer Research and Treatment
- Pancreatic and Hepatic Oncology Research
- Gastrointestinal Tumor Research and Treatment
- Renal cell carcinoma treatment
- Colorectal Cancer Surgical Treatments
- Pancreatitis Pathology and Treatment
- Gut microbiota and health
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Esophageal and GI Pathology
- Colorectal and Anal Carcinomas
- Urinary and Genital Oncology Studies
Peking Union Medical College Hospital
2024-2025
Tianjin Medical University
2025
Second Hospital of Tianjin Medical University
2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2020-2025
Beijing University of Chemical Technology
2024
Abstract Purpose: Combinations of immune checkpoint inhibitors and nab-paclitaxel have improved outcomes in advanced urothelial carcinoma muscle-invasive bladder cancer. This study evaluates the safety efficacy tislelizumab combined with low-dose extensive very high-risk (VHR) non-muscle-invasive cancer (NMIBC). Patients Methods: TRUCE-02 was a single-arm phase 2 trial that included 63 patients visually incomplete resection and/or high-volume high-grade T1 tumors (with or without situ), who...
<div>AbstractPurpose:<p>Combinations of immune checkpoint inhibitors and nab-paclitaxel have improved outcomes in advanced urothelial carcinoma muscle-invasive bladder cancer. This study evaluates the safety efficacy tislelizumab combined with low-dose extensive very high–risk non–muscle-invasive cancer.</p>Patients Methods:<p>TRUCE-02 was a single-arm phase II trial that included 63 patients visually incomplete resection and/or high-volume high-grade T1 tumors (with...
<p>Supplementary Figure S1. Schematic protocol diagram.</p>
<p>Supplementary Figure S2. Duration of complete response any disease.</p>
Significant gaps exist in understanding the gastrointestinal microbiota patients with pancreatic cancer (PCA) versus benign or low-grade malignant tumors (NPCA). This study aimed to analyze these characteristics and explore their potential use distinguishing lesions. Between September 2020 May 2024, fecal oral samples were collected from 121 undergoing surgical resection diagnostic biopsy of lesions, including 75 PCA 46 NPCA, 16s rRNA sequencing was performed. Random forest models based...
Objective: To investigate the associations between genetic variations of apoptosis genes and adverse events postoperative concurrent chemoradiotherapy in patients with rectal cancer. Methods: We enrolled 362 stage Ⅱ to Ⅲ cancer who received chemoradiotherapy. Whole blood sample (2 ml) was collected from patient at time enrollment before therapy. Sequenom MassARRAY used detect genotypes 29 haplotype-tagging single nucleotide polymorphisms (htSNPs) eight genes, including Fas cell surface death...